Madam Chair, I thank my colleague for the question. I appreciate her.
This is part of the national pharmacare challenge, to find a way to reduce the cost of and increase access to drugs, for rare diseases in particular.
In this context, we have announced that we will develop a strategy to combat rare diseases with an annual investment of $500 million in the coming years.